Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.

BJ, Giantonio; PJ, Catalano; NJ, Meropol; PJ, O'Dwyer; EP, Mitchell; SR, Alberts; MA, Schwartz; AB 3rd, Benson

doi:10.1200/jco.2006.09.6305

Public

Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.

Shared by NobleBlocks on Apr 1, 2007 • 12:00 AM UTC

Authors:

Giantonio BJ

Catalano PJ

Meropol NJ

Abstract

<h4>Purpose</h4>Colorectal cancer is the second leading cause of cancer mortality in the United States. Antiangiogenic therapy with bevacizumab combined with chemotherapy improves survival in previously untreated metastatic colorectal cancer. This study was conducted to determine the effect of bevac...

Discussions